Cosette Pharmaceuticals Announces the launch of Griseofulvin Oral Suspension, 125 mg/5 mL.

Launch Enables Access To Patients And Providers, Alleviating Supply Chain Constraints

Apurva Saraf, President and CEO, Coesette Pharmaceuticals. (Photo: Business Wire)

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc ("Cosette") began shipping Griseofulvin Oral Suspension, 125 mg/5 mL (0713-0850-04) into all channels in the United States.

This launch will provide much needed access to patients and providers for a product which has been supply constrained. The finished product will be manufactured in the United States.

Apurva Saraf, President and CEO of Cosette Pharma, stated, "This approval and immediate launch demonstrates our ability to continue transforming Cosette, by launching important products through our drug development, supply chain management and manufacturing expertise. This is in addition to a long list of new product launches this year, and is a testament to how we are Innovating Every Day."

According to IQVIA™, U.S. market annual sales for the 12 months ended October 2022 for Griseofulvin Oral Suspension, 125 mg/5 mL is estimated to be approximately $12 million.

See the Full Prescribing Information and Instructions for Use for Griseofulvin Oral Suspension, 125 mg/5 mL. www.dailymed.com

About Cosette Pharmaceuticals, Inc.:

Cosette Pharmaceuticals, Inc. is a US-based, fully integrated pharmaceutical company with capabilities in product development, manufacturing, and commercial operations. The current products focus on complex dosage forms including topical creams, ointments, oral liquids/solutions, suppositories, and injectables. Cosette has a long history of quality manufacturing, consistent supply, and commercialization success, including two sites (New Jersey and North Carolina) supported by more than 350+ dedicated employees across all functional areas. Cosette has a fast-growing portfolio of branded pharmaceuticals, consisting of products in cardiology, women’s health and pediatrics. Cosette is backed by Avista Capital Partners, a healthcare focused private equity firm. www.cosettepharma.com

Contacts

Serge Ilin-Schneider: bd@cosettepharma.com
Kian Kazemi: sales@cosettepharma.com

Industry:

Cosette Pharmaceuticals, Inc.

Details

Headquarters: Bridgewater, New Jersey, USA

Website: https://cosettepharma.com

CEO: Apurva Saraf

Employees: 350

Organization: PRI

Release Summary

Cosette Pharmaceuticals Announces Launch of Griseofulvin Oral Suspension,125 mg/5 mL. Enables Access To Patients, Alleviates Supply Chain Constraints

Release Versions

Hashtags

#pharmaceuticalindustry

#pharmaceuticalmanufacturing

#pharmaceuticals

#privateequity

Contacts

Serge Ilin-Schneider: bd@cosettepharma.com
Kian Kazemi: sales@cosettepharma.com

Social Media Profiles

Cosette Pharmaceuticals, Inc.

More News From Cosette Pharmaceuticals, Inc.

Cosette Pharmaceuticals Appoints Jeff Neubig as Vice President, Quality and Regulatory Affairs

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated, pharmaceutical company, announced today that it has appointed Jeff Neubig as Vice President, Quality and Regulatory Affairs. In this critical role, Jeff will lead Cosette’s best-in-class quality and regulatory affairs organizations, maintaining the company’s rigorous quality standards and further establishing Cosette’s strong position as a respected and reliable supplier of high-quality medicines....

Cosette Pharmaceuticals Announces Acquisition of Mayne Pharma, Transforming Company into a Leader in Women’s Health and Dermatology

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated, pharmaceutical company, announced today that it has entered into a definitive agreement to acquire all the outstanding shares of Mayne Pharma Group Limited (ASX: Ticker MYX) (Mayne Pharma) at AUD$7.40/share for a total consideration of approximately USD $430 Million. The Boards of Directors of both companies have approved the transaction and Mayne Pharma’s Board of Directors has unanimously recomm...